Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $12.68M rose 186.6% year over year, ahead of the +135.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at +188.3% a year.
Context
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +186.6% holds above the trailing-twelve-month pace of +135.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 22.93M USD
- Year-over-year change
- +32.2%
- 4-year CAGR
- +203.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.93M | +32.2% |
| FY2024 | 2024-12-31 | 17.35M | +460.3% |
| FY2023 | 2023-12-31 | 3.1M | +223.5% |
| FY2022 | 2022-12-31 | 957K | +253.1% |
| FY2021 | 2021-12-31 | 271K | — |
Other Income / Expenses vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 other income / expenses of $47.3M is the 2nd highest of the 10 companies compared; the peer median is $14.93M.
- Its year-over-year change of +135.6% is the highest of 10, against a peer median of -35.1%.
- Over three fiscal years its annual growth of +188.3% compares with a peer median of +42.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.9M | -35.1% | — | 1.4% | |
| LTM Sep 2026 | $47.3M | +135.6% | +188.3% | — | |
| LTM Sep 2026 | $35.81M | +15.2% | +93.5% | — | |
| LTM Jun 2026 | $31.35M | -42.6% | +42.7% | 869.8% | |
| LTM Sep 2026 | $26.16M | -20.1% | +49.8% | 2.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M | +11.7% | — | 74.6% |
| LTM Dec 2025 | $4.67M | -45.3% | +14.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Jun 2026 | -$2.54M | +86.5% | — | 0.3% | |
| LTM Jun 2026 | -$11.65M | -164.6% | — | 1.4% | |
| Peer median (excluding PRAX) | $14.93M | -35.1% | +42.7% | 1.8% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.